Cancer giants BMS, AstraZeneca clash in new checkpoint inhibitor patent suit – FiercePharma

21st March 2022

Cancer giants BMS, AstraZeneca clash in new checkpoint inhibitor patent suit FiercePharma

OPUS IP on X (formerly Twitter)…

Twitter feed is not available at the moment.

RECENT PATENT NEWS…

The great wave of patents that will expire in 2028: why pharmaceuticals are seeking mergers - democrata.es
Irides: Weekly global patent litigation update (via Passle) - Bristows
Dutch simplified lithium refiner Lithium Ark secures another patent ahead of commercialisation - Engineering News
Ascendis Pharma settles patent dispute with US-based Biomarin - medwatch.com

UK BUSINESS NEWS…

AI could cause global economic downturn, Andrew Bailey warns G20
Shein valued at $26bn after long-awaited stock market debut
Children sleeping on piles of clothes, says charity
I'm on a mission to convince people to work less

Designed by Industrial Action

Copyright © 2026 OPUS IP Limited. All Rights Reserved

OPUS IP Limited: COMPANY & OTHER LEGAL INFORMATION